435 related articles for article (PubMed ID: 28361224)
1. Immunotherapy for Esophageal Squamous Cell Carcinoma.
Kojima T; Doi T
Curr Oncol Rep; 2017 May; 19(5):33. PubMed ID: 28361224
[TBL] [Abstract][Full Text] [Related]
2. Current status of cancer immunotherapy for esophageal squamous cell carcinoma.
Kono K; Mimura K; Yamada R; Ujiie D; Hayase S; Tada T; Hanayama H; Min AKT; Shibata M; Momma T; Saze Z; Ohki S
Esophagus; 2018 Jan; 15(1):1-9. PubMed ID: 29892809
[TBL] [Abstract][Full Text] [Related]
3. Increased Tim-3
Kato R; Yamasaki M; Urakawa S; Nishida K; Makino T; Morimoto-Okazawa A; Kawashima A; Iwahori K; Suzuki S; Ueda R; Mori M; Satoh T; Doki Y; Wada H
Cancer Immunol Immunother; 2018 Nov; 67(11):1673-1683. PubMed ID: 30128737
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for esophageal cancer: a 2019 update.
Schizas D; Charalampakis N; Kole C; Mylonas KS; Katsaros I; Zhao M; Ajani JA; Psyrri A; Karamouzis MV; Liakakos T
Immunotherapy; 2020 Feb; 12(3):203-218. PubMed ID: 32208794
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
Alsina M; Moehler M; Lorenzen S
Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Suzuki Y; Mimura K; Yoshimoto Y; Watanabe M; Ohkubo Y; Izawa S; Murata K; Fujii H; Nakano T; Kono K
Cancer Res; 2012 Aug; 72(16):3967-76. PubMed ID: 22700877
[TBL] [Abstract][Full Text] [Related]
7. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
Moy JD; Moskovitz JM; Ferris RL
Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
[TBL] [Abstract][Full Text] [Related]
8. Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer.
Zingg U; Montani M; Frey DM; Dirnhofer S; Went P; Oertli D
Eur J Surg Oncol; 2009 Dec; 35(12):1268-72. PubMed ID: 19632080
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for esophageal squamous cell carcinoma: a review.
Mimura K; Yamada L; Ujiie D; Hayase S; Tada T; Hanayama H; Thar Min AK; Shibata M; Momma T; Saze Z; Ohki S; Kono K
Fukushima J Med Sci; 2018 Aug; 64(2):46-53. PubMed ID: 30058598
[TBL] [Abstract][Full Text] [Related]
10. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.
Tsuchikawa T; Miyamoto M; Yamamura Y; Shichinohe T; Hirano S; Kondo S
Ann Surg Oncol; 2012 May; 19(5):1713-9. PubMed ID: 21822560
[TBL] [Abstract][Full Text] [Related]
11. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer.
Yang J; Janjigian YY
Thorac Surg Clin; 2022 Nov; 32(4):467-478. PubMed ID: 36266034
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma.
Wang J; Jia Y; Wang N; Zhang X; Tan B; Zhang G; Cheng Y
J Transl Med; 2014 Jan; 12():7. PubMed ID: 24397835
[TBL] [Abstract][Full Text] [Related]
14. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Ikeda G; Miyakoshi J; Yamamoto S; Kato K
Future Oncol; 2024 Apr; 20(11):665-677. PubMed ID: 38126175
[TBL] [Abstract][Full Text] [Related]
16. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model.
Tao H; Qian P; Wang F; Yu H; Guo Y
Oncol Res; 2017 Nov; 25(9):1579-1587. PubMed ID: 28337964
[TBL] [Abstract][Full Text] [Related]
19. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
20. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]